JPRN-UMIN000014711已完成2 期
Garenoxacin to Prevent Febrile Neutropenia in Chemotherapy for Lung Cancer - Garenoxacin to Prevent Febrile Neutropenia in Chemotherapy for Lung Cancer
Institute of Biomedical Research and Innovation0 个研究点目标入组 30 人开始时间: 2014年7月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Tumor fever 2)Complication such as severe infection or comobidities 3)History of severe allergic reaction 4)History of epilepsy or convulsant 5)Clinically significant heart disease 6)Uncontrolled diabetes 7)Routine use of NSAIDS 8)Routine use of steroids or immuno-suppressant 9)Chronic aspiration 10)Clinically significant psychological problems 11)unsuitable patients whom physitians consider
研究者
相似试验
已完成
3 期
Prophylaxis of febrile neutropenia by reducing chemotherapy-induced gastrointestinal mucosal injuryfebrile neutropeniaJPRN-UMIN000011065Juntendo University School of Medicine75
已完成
不适用
Effect of Garenoxacin to fever and pro-inflamatory cytokine with bronchoscopyfever and increase of pro-inflamatory cytokine with bronchoalveolar lavageJPRN-UMIN000004387Keio University Hospital60
已完成
不适用
Cohort Study on Febrile Neutropenia in Adjuvant Chemotherapy for Breast Cancer PatientsBreast CancerJPRN-UMIN000017857CSPOR-BC1,000
尚未招募
不适用
A study to observation patients with cancer who develop fever on chemotherapy due to low white cell countCTRI/2021/09/036930Tata Memorial Hospital
已完成
3 期
EVOFLOXACIN PREVENTS FEBRILE NEUTROPENIA DURING CYTARABINE CONSOLIDATION (IDAC/HIDAC) IN ACUTE MYELOID LEUKEMIAWe aimed to evaluate the efficacy of levofloxacin for febrile neutropenia prevention following cytarabine containing consolidation chemotherapy (intermediate dose-IDAC or high dose-HIDAC) in newly diagnosed AML patients.AML , febrile neutropenia, levofloxacinTCTR20240401009none36